American Society of Hirudotherapy

Purification and characterization of a novel thermostable anticoagulant protein from medicinal leech Whitmania pigra Whitman

Protein purification study published in Journal of Ethnopharmacology (2022)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSalivary PharmacologyZhang Y et al. · Journal of Ethnopharmacology, 2022

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: The prevalence of cardiovascular disease (CVD) is increasing worldwide. Despite significant improvements in novel targeted treatment agents, natural products purified from medicinal animals with minimal side effects have attracted much attention. Several native proteins explored from suck-blood leeches, such as non-thermostable hirudin and its variants, revealed potent anticoagulant activity. Traditional Chinese medicine clinics have proved that non-suck-blood leech Whitmania pigra Whitman (W. pigra) also played notable roles in CVD treatments even after decoction. However, only a few natural proteins and peptides have been identified from the fresh material of this medicinal species. AIM OF THE STUDY: We aimed to purify and characterize thermostable anticoagulant proteins from W. pigra for further development of a therapeutic agent for thrombosis. MATERIALS AND METHODS: W. pigra crude extract was prepared by decoction in water. Anticoagulant proteins were purified by DEAE cellulose DE-52, Sephadex G-75, and reversed-phase liquid chromatography sequentially and analyzed by SDS-PAGE and LC-MS/MS for structural information. In addition, we conducted in vitro anticoagulant experiments, including plasma recalcification time (PRT) assay, fibrinolytic assay, activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (Fib) assay, and cell viability assays. Furthermore, a carrageenan-induced chronic thromboembolism model was employed in ICR mice, and four coagulation factors (APTT, PT, TT, and Fib) activities were determined after intragastric administration. RESULTS: The anticoagulant protein WP-77 has a relative molecular weight of ca. 20.8 kDa. It was effective over a broad temperature range from 20 °C to 100 °C and a pH 2-8 condition. The anticoagulant activity of WP-77 was retained after incubation with pepsin but was greatly inhibited by trypsin (P < 0.01). It significantly prolonged APTT and TT (P < 0.05) but had little effect on PT and Fib in vitro. Furthermore, WP-77 of a low concentration resulted in the recovery of injured EA.hy926 by thrombin. The protein also significantly prolonged APTT and TT (P < 0.01) and inhibited thrombus formation in carrageenan-induced thrombosis mice, demonstrating its antithrombotic effect in vivo. CONCLUSION: Our results suggest that WP-77 from W. pigra plays a distinct role in treating thrombotic diseases, and it is an essential substance of anticoagulant activity of non-suck-blood medicinal leeches. This thermostable anticoagulant protein could be a promising candidate for the development of clinical antithrombosis medicines.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsAnticoagulantsBiological ProductsBlood CoagulationCell LineChromatography, LiquidComplex MixturesDisease Models, AnimalEndothelial CellsHumansLeechesMaleMedicine, Chinese TraditionalMiceMice, Inbred ICRProteinsTandem Mass SpectrometryTemperatureThrombosis

Summary

Novel WP-77 anticoagulant protein (20.8 kDa) from non-suck-blood Whitmania pigra was thermostable from 20 to 100°C and pH 2-8, prolonged APTT and TT, and inhibited thrombus formation in carrageenan-induced thrombosis mice — supports development of a heat-resistant anticoagulant drug candidate.

Why This Matters for Hirudotherapy

This study purified and characterized a novel thermostable anticoagulant protein, WP-77 (~20.8 kDa), from the non-suck-blood medicinal leech Whitmania pigra via water decoction and chromatography. WP-77 withstood broad temperature (20–100 °C) and pH (2–8) ranges, significantly prolonged APTT and TT in vitro, protected thrombin-injured EA.hy926 endothelial cells, and inhibited thrombus formation in a carrageenan-induced mouse thrombosis model after intragastric administration. This work expands knowledge of thermostable bioactive anticoagulants from a medicinal leech species traditionally used in Chinese medicine, complementing known leech-derived agents like hirudin. The in vivo data come from a single murine thrombosis model and the findings are preclinical; no human efficacy or safety data are presented, and clinical development claims are speculative.

Citation

Reference (Vancouver style)

Zhang Y, Yang R, Wang L, Li Y, Han J, Yang Y, et al. Purification and characterization of a novel thermostable anticoagulant protein from medicinal leech Whitmania pigra Whitman. J Ethnopharmacol. 2022;288:114990. doi:10.1016/j.jep.2022.114990. PMID: 35032585

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.